Intravenous immunoglobulin has been used after bone marrow transplants to prevent infections and acute graft-versus-host disease. However, the minimum dose required for protection is unknown. This may have significant economic implications. A multicenter randomized clinical trial compared the impact of two intravenous immunoglobulin doses on systemic infections and acute graft-versus-host disease in transplant recipients. Either 250 mg/kg or 500 mg/kg was given weekly from day −8 to day +111. Multivariate analysis was used to assess the effect of dose and other risk factors on event-free survival, systemic infection, and acute graftversus-host disease. The two-dose cohorts had similar event-free survival and infection frequencies. The higher dose was associated with less acute graft-versushost disease (P = 0.03). Keywords: intravenous immunoglobulin; infection; graft-versus-host disease; allogeneic bone marrow transplantation Intravenous immunoglobulin (IVIG) is often given after allogeneic bone marrow transplants to decrease incidence of interstitial pneumonia, particularly that related to cytomegalovirus (CMV).
Intravenous immunoglobulin (IVIG) is often given after allogeneic bone marrow transplants to decrease incidence of interstitial pneumonia, particularly that related to cytomegalovirus (CMV). [1] [2] [3] [4] Other studies of IVIG report less systemic bacterial infections and acute graft-versus-host disease (GVHD). [4] [5] [6] [7] Although a weekly IVIG dose of 500 mg/kg is often given, the optimum dose is unknown. We conducted a multicenter randomized study to compare incidence of systemic infections and acute GVHD after 250 and 500 mg/kg of IVIG.
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Patients and methods

Study design
Three hundred and fifty patients transplanted in 10 centers entered the trial. Eligible patients were those without documented infection at entry who had an Institutional Review Board-approved consent form. Patients were stratified by age (Ͻ21 vs Ͼ21), CMV serology (donor/recipient negative vs either positive), and HLA-match (6 of 6 antigen match vs other), and randomized to receive either 250 mg/kg or 500 mg/kg of IVIG weekly from day −8 to day +111 post-transplant (18 doses). All donors were related. Pre-study forms and study flow sheets provided weekly information for 24 weeks on the clinical status and development of any infection or acute GVHD requiring treatment. An off-study form was completed either at 24 weeks post-transplant, if they had completed the whole IVIG course, or earlier if they were taken off study. The reasons for removal from study were: (1) death; (2) relapse; (3) deviation from the protocol such as termination of IVIG use or use of a different dosing schedule.
IVIG
Gammagard (Baxter Hyland, Glendale, CA, USA) was used in this study. This is a native monomeric IgG preparation produced by the combination of Cohn fractionation with DEAE-Sephadex ion exchange chromatography. This procedure avoids the use of low pH proteolytic enzymes or other chemical purification methods that tend to reduce the required biologic activity. Commercially available lots had minimal inter-lot variability. 8 
Definition of terms
Infections were identified by organism and site of involvement. Severity was graded as follows: (1) grade 1: mild, consisting of either local or systemic infection with no reported symptoms and/or lasting р3 days; (2) grade 2: moderate to severe symptomatic systemic infection and/or lasting Ͼ3 days but non-fatal; (3) grade 3: fatal infections. Bone marrow engraftment was defined as neutrophils 0.5 × 10 9 /l. Acute GVHD in this study was considered present if the overall grade was II or greater according to the system of Glucksberg et al. 
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Supportive care
Patients were housed in laminar air flow or HEPA-filtered rooms. Hand washing was carried out before every patient contact. Patients also received low-bacterial diets, and prophylaxis with cotrimoxazole or pentamidine against Pneumocystis carinii infections. Many received acyclovir against herpes virus reactivation and fluconazole against fungal infections. Almost half of the patients received nonabsorbable prophylactic oral antibiotics. The CMVseronegative patients received only CMV-negative blood products; seropositive patients received CMV-unscreened blood products. All blood products were irradiated to 15 Gy. Blood transfusions were given to keep hematocrits у25% and platelets у20 × 10 9 /l. Febrile (T у38.5°C) patients with neutropenia received broad-spectrum intravenous antibiotics according to each investigator's discretion, after cultures were obtained. Amphotericin B was added if a patient continued febrile after 3-5 days with no identified source. 
Statistics
Comparisons of proportions and survivorship curves were analyzed. The former included overall deaths, death from infections and deaths from acute GVHD with no evidence of infection by cultures and/or post-mortem examinations. Those with evidence of both were classified as infectionrelated deaths but were included also in acute GVHD incidence. Survivorship data included event-free survival (EFS), incidence of fatal infections, of non-fatal infections, of engraftment and of acute GVHD. For survival analyses, follow-up was truncated to 160 days to avoid the bias caused by selective follow-up in estimating the survival curves. Pearson chi-square tests were used to compare proportions. Survival curves were estimated using the KaplanMeier method and compared using logrank tests and multiproportional hazards regression models. Dependent variables analyzed were: (1) 
Results
Patients
Eighteen patients were excluded because of inadequate data or protocol deviation. The remaining 332 patients form the basis of this report. Median age was 21 years (mean, 22 years). Distribution of risk factors was balanced in the two arms (Table 1) . Thirty-six subjects were lost to follow-up without an event before 160 days. Of these, 19 were followed for less than 140 days. The reasons for early study termination were unrelated to the dose of IVIG given (Table 2) .
Event-free survival
There was no significant relationship between IVIG dose and EFS (Figure 1) . With a 90% probability of detecting a 57% change in the relative hazard, there was also no significant difference in EFS after adjusting for age, CMV status and HLA matching in a multivariate proportional hazards model. 
Fatal infections and infection-specific survival
Infection accounted for, or played a major role in 77 (59%) of the 131 deaths. There was no significant difference in the infection risk between the two IVIG arms (P = 0.8). The study had 90% power to detect a 54% difference in relative hazard of infection and the estimated hazard of infection on the low-dose arm, relative to the high-dose arm, was between 0.60 and 1.48, adjusted for age, CMV status and HLA matching, using a proportional hazards regression. Age (P = 0.0001) was the only risk factor significantly associated with fatal infection (Figure 2 ). IVIG dose did not interact with age to explain this difference in incidence of fatal infections (P Ͼ 0.7).
GVHD
Of the 332 patients, 164 (49.4%) developed grade II or higher acute GVHD. Median time of onset was 2.5 weeks. The higher dose of IVIG was associated with less acute GVHD (approximately 58% vs 44%: P = 0.03 log rank: Figure 3 ).
Discussion
Similar rates of fatal and non-fatal infections and EFS were seen in both arms. This is consistent with the findings of other studies using different IVIG doses. 10 Although this trial was not designed primarily to address whether IVIG reduces acute GVHD, other controlled trials report significantly less acute GVHD in people receiving IVIG (500-1000 mg/kg) weekly for 3-4 months post-transplant. 11, 12 Meta-analysis of controlled trials on 379 patients found less acute GVHD (RR = 0.68) in IVIG recipients relative to untreated controls. 11 One study showed less acute GVHD and suggested it may depend on immunoglobulin trough levels. 12 Several studies have reported the protective effect of IVIG against CMV infection in CMV-seropositive patients. [13] [14] [15] [16] Among CMV-positive recipients/donors, we found no significant difference in CMV infections between the two doses. There were more fatal CMV infections amongst CMV-positive patients in both arms.
The toxicity attributable to IVIG was minimal. However, it is expensive and transmission of infection has been reported. 17, 18 Cost considerations and advances in infection prevention explain the trend in using IVIG selectively.
